KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Treasury Shares (2018 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Treasury Shares for 12 consecutive years, with $779000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares fell 54.84% year-over-year to $779000.0, compared with a TTM value of $779000.0 through Dec 2025, down 54.84%, and an annual FY2025 reading of $779000.0, down 54.84% over the prior year.
  • Treasury Shares was $779000.0 for Q4 2025 at Alnylam Pharmaceuticals, down from $1.7 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.7 million in Q4 2024 and bottomed at $779000.0 in Q4 2025.
  • Average Treasury Shares over 5 years is $1.2 million, with a median of $1.1 million recorded in 2021.
  • The sharpest move saw Treasury Shares skyrocketed 870.94% in 2021, then crashed 54.84% in 2025.
  • Year by year, Treasury Shares stood at $1.1 million in 2021, then increased by 5.19% to $1.2 million in 2022, then decreased by 14.23% to $1.0 million in 2023, then soared by 68.29% to $1.7 million in 2024, then plummeted by 54.84% to $779000.0 in 2025.
  • Business Quant data shows Treasury Shares for ALNY at $779000.0 in Q4 2025, $1.7 million in Q4 2024, and $1.0 million in Q4 2023.